Fig. 3: Progression of summary Simple Sum Score sensor outcome measure and MDS-UPDRS Part III in individuals with PD on placebo (black) and prasinezumab (blue). | npj Digital Medicine

Fig. 3: Progression of summary Simple Sum Score sensor outcome measure and MDS-UPDRS Part III in individuals with PD on placebo (black) and prasinezumab (blue).

From: Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab

Fig. 3

a Progression on motor signs in the pooled early- and delayed-start prasinezumab groups as measured by Simple Sum v1.2 score (results from the linear mixed effects models (LMEs) are reported) and (b) the MDS-UPDRS Part III. Only data collected prior to the start of dopaminergic therapy are analyzed and plotted. For both metrics, higher scores indicate more severe motor signs. b is adapted from ref. 4, Copyright ©2022 Massachusetts Medical Society. Reprinted with permission.

Back to article page